Scholars Central

Research articlePublished 2018

In vitro Drug-Drug Interaction Studies of Apixaban with Atorvastatin by HPTLC Method

Authors: Sangeetha RK, Ravi TK

Journal of Drug Metabolism & Toxicology

Volume 9 · Issue 3 · Pages 1–4

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Poly-pharmacy of cardiovascular drugs is a common cause of a few unexpected drug-drug interactions (DDI) which may lead to the occurrence of the adverse effects of the drugs co-administered. The High Performance Thin Layer Chromatography method was adopted for the analysis of apixaban and atorvastatin. The method validation for the individual drugs was carried out according to the ICH guidelines. The validated method was applied for the In vitro drug-drug interaction studies at the biological pH of stomach at 4.0, of blood at 7.4 and intestinal condition at 9.0. The aim of the studyis to evaluate the effect of atorvastatin under the simulated conditions of the human body. The In vitro drug-drug interaction studies suggest the drug apixaban does not have any profound change at pH 4 and 9 when present with atorvastatin. When apixaban and atorvastatin are present at a pH 7.4 the significant variation in the detector response is indicative of the decrease in the level of apixaban.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Drug Metabolism & Toxicology
  • SubjectDiabetes & Endocrinology
  • SubjectPharmaceutical Sciences
  • SubjectToxicology
  • BylineArticles whose byline prints “Sangeetha RK”
  • BylineArticles whose byline prints “Ravi TK”